Suppr超能文献

运动员长 QT 综合征或遗传性心脏病致心源性猝死的复出运动。

Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death.

机构信息

Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA.

Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA; Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

J Am Coll Cardiol. 2021 Aug 10;78(6):594-604. doi: 10.1016/j.jacc.2021.04.026.

Abstract

BACKGROUND

Within the last 5 years, cardiac society guidelines have begun to acknowledge shared decision making (SDM) for the athlete with sudden cardiac death-predisposing genetic heart diseases (GHDs), such as long QT syndrome (LQTS), and the possibility for that athlete's return to play. Previously, international guidelines embraced a de facto disqualification for all such athletes including athletes with solely a positive genetic test in Europe.

OBJECTIVES

This study sought to examine the prevalence and outcomes of athletes with sudden cardiac death-predisposing GHDs, particularly LQTS, after their return to play.

METHODS

A retrospective review of the electronic medical record was performed on all athletes with GHD, with a primary analysis for those with LQTS, who were evaluated, risk stratified, and treated in Mayo Clinic's Windland Smith Rice Genetic Heart Rhythm Clinic by a single genetic cardiologist between July 1, 2000, and July 31, 2020.

RESULTS

There were 672 athletes with GHD overall including 494 athletes with LQTS (231 female athletes [46.8%]; mean age at diagnosis 14.8 ± 10.5 years; mean follow-up 4.2 ± 4.8 years) who were given return-to-play approval. Overall, 79 of 494 athletes with LQTS (16.0%) were symptomatic before diagnosis, and 58 (11.7%) had an implantable cardioverter-defibrillator. In 2,056 combined years of follow-up, there was no GHD-sports associated mortality. Instead, 29 patients (5.9%) had ≥1 nonlethal, LQTS-associated breakthrough cardiac event. Of those, 15 (3.0%) were athletes at the time of the breakthrough cardiac event, with 3 (0.6%) experiencing a sports-related breakthrough cardiac event, and 12 (2.4%) a non-sports-related event. Overall, the event rate was 1.16 nonlethal events per 100 athlete-years of follow-up.

CONCLUSIONS

This 20-year single center experience challenges the status quo of disqualification for all athletes with LQTS and provides additional observational evidence, albeit from a single center, in support of the more contemporary SDM approaches to this complex issue.

摘要

背景

在过去的 5 年中,心脏协会指南开始承认患有遗传性心脏病(GHD)的运动员(如长 QT 综合征,LQTS)存在共同决策(SDM),并可能重返运动。此前,国际指南在欧洲接受了实际上对所有此类运动员的取消资格,包括仅基因检测阳性的运动员。

目的

本研究旨在检查患有遗传性心脏病(GHD),尤其是 LQTS 的运动员重返运动后的患病率和结局。

方法

对所有 GHD 运动员的电子病历进行回顾性分析,主要分析 LQTS 运动员,这些运动员由一位基因心脏病专家在梅奥诊所的温德兰·史密斯·赖斯遗传心律失常诊所进行评估、风险分层和治疗,时间为 2000 年 7 月 1 日至 2020 年 7 月 31 日。

结果

共有 672 名 GHD 运动员,其中 494 名患有 LQTS(231 名女性运动员[46.8%];诊断时的平均年龄为 14.8 ± 10.5 岁;平均随访时间为 4.2 ± 4.8 年)获得重返运动的批准。总体而言,494 名患有 LQTS 的运动员中有 79 名(16.0%)在诊断前有症状,58 名(11.7%)有植入式心脏复律除颤器。在 2056 年的随访中,GHD 与运动相关的死亡率为零。相反,29 名患者(5.9%)发生了≥1 次非致命性、与 LQTS 相关的突破性心脏事件。其中,15 名(3.0%)是在突破性心脏事件时的运动员,其中 3 名(0.6%)发生了与运动相关的突破性心脏事件,12 名(2.4%)发生了与运动无关的事件。总体而言,非致命性事件的发生率为每 100 名运动员年 1.16 次。

结论

这项为期 20 年的单中心经验挑战了对所有 LQTS 运动员取消资格的现状,并提供了额外的观察证据,尽管来自单一中心,但支持了对这一复杂问题的更现代的 SDM 方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验